Latest News

The Wall Street Journal: Merck nears deal for rare-disease-drug maker Acceleron

Merck is in advanced talks to acquire Acceleron Pharma Inc., according to people familiar with the matter, in a move that would bolster the pharmaceutical giant’s rare-disease business.

The deal for Acceleron, which has a market value of around $11 billion, could be announced this week, assuming talks don’t fall apart, the people said.

Should a deal come together, it would be one of Merck’s
MRK,
-0.34%

biggest and represent a bet on the treatments for the respiratory and blood diseases that Acceleron
XLRN,
+6.69%

specializes in.

Merck appears to have beaten out other potential suitors for Acceleron including Bristol Myers Squibb Co.,
BMY,
-0.65%

which already owns a big stake in the company.

An expanded version of this story is available at WSJ.com

You may also like

Leave a reply

Your email address will not be published. Required fields are marked *

More in Latest News